ATE261314T1 - P53 impfstoff - Google Patents

P53 impfstoff

Info

Publication number
ATE261314T1
ATE261314T1 AT93918436T AT93918436T ATE261314T1 AT E261314 T1 ATE261314 T1 AT E261314T1 AT 93918436 T AT93918436 T AT 93918436T AT 93918436 T AT93918436 T AT 93918436T AT E261314 T1 ATE261314 T1 AT E261314T1
Authority
AT
Austria
Prior art keywords
vaccine
mutant
wild
mammal
protein
Prior art date
Application number
AT93918436T
Other languages
English (en)
Inventor
Arnold J Levine
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Application granted granted Critical
Publication of ATE261314T1 publication Critical patent/ATE261314T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Developers In Electrophotography (AREA)
AT93918436T 1992-07-22 1993-07-22 P53 impfstoff ATE261314T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91829292A 1992-07-22 1992-07-22
US1549393A 1993-02-09 1993-02-09
PCT/US1993/007069 WO1994002167A1 (en) 1992-07-22 1993-07-22 p53 VACCINE

Publications (1)

Publication Number Publication Date
ATE261314T1 true ATE261314T1 (de) 2004-03-15

Family

ID=26687448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918436T ATE261314T1 (de) 1992-07-22 1993-07-22 P53 impfstoff

Country Status (7)

Country Link
EP (2) EP0651653B1 (de)
JP (2) JPH07509251A (de)
AT (1) ATE261314T1 (de)
AU (1) AU4788693A (de)
CA (1) CA2140624C (de)
DE (1) DE69333448D1 (de)
WO (1) WO1994002167A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010423A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
KR0158430B1 (ko) * 1994-10-07 1998-12-01 허영섭 p53 단백질을 이용한 B형 간염 바이러스의 복제 억제방법
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
WO1998014207A1 (en) * 1996-10-01 1998-04-09 Dana-Farber Cancer Institute Immunological therapy for cancer
AU4907797A (en) * 1996-10-10 1998-05-05 Wistar Institute Of Anatomy And Biology, The Methods and compositions for inducing a protective immune response to cancers
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
EP1360496A4 (de) * 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
US20080125404A1 (en) 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
JP2008012964A (ja) 2006-07-03 2008-01-24 Yamaha Marine Co Ltd リモコン装置、及び船舶
WO2009088256A2 (ko) 2008-01-09 2009-07-16 Konkuk University Industrial Cooperation Corp 배큘로바이러스-기반 백신
EP2496268A4 (de) 2009-11-06 2013-06-19 Univ Chung Ang Ind Genabgabesysteme auf nanopartikelbasis
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
CN108289920A (zh) 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
CN111630159A (zh) 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
JPH07501942A (ja) * 1991-11-29 1995-03-02 カイロン　コーポレイション 抗ガン免疫療法用ベクター構成体
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.

Also Published As

Publication number Publication date
EP0651653B1 (de) 2004-03-10
EP1421947A1 (de) 2004-05-26
WO1994002167A1 (en) 1994-02-03
EP0651653A1 (de) 1995-05-10
CA2140624C (en) 2001-05-01
CA2140624A1 (en) 1994-02-03
JPH07509251A (ja) 1995-10-12
JP2003300903A (ja) 2003-10-21
EP0651653A4 (de) 1996-07-17
AU4788693A (en) 1994-02-14
DE69333448D1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE261314T1 (de) P53 impfstoff
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
MY113428A (en) Hepatitis b vaccine
CY2593B2 (en) Adjuvants for vaccines
PL304419A1 (en) Urease based vaccine against heliobacter infections
IT1205820B (it) Adiuvante immunologico per vaccini polisaccaridici
ZA932491B (en) Vaccines
FI851859A0 (fi) Antigenpreparat och isolering av saodana preparat.
EP0203676A3 (en) Vaccine for generating an immunogenic t cell response protective against a virus
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
DK0614355T3 (da) Antitumorvacciner
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
AU2032988A (en) A genus-specific listeria antigen identified by monoclonal antibodies
DE69626642D1 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
DK0570682T3 (da) Syntetiske lipid-A-glycoconjugat-antigener til anvendelse i vacciner
IT1177974B (it) Composizione comprendente endotossina detossificata raffinata
EP0589348A3 (de) Verfahren zur immunchemischen Quantifizierung von inaktivierten, immunreaktiven Antigenen.
DE69322960D1 (de) Empfängnisverhütender impfstoff
ATE159758T1 (de) Azelluläre impfstoffe
IT219552Z2 (it) Dispositivo di bloccaggio automatico per rotelle di poltroncine e simili
IT8960392V0 (it) Dispositivo autoirrorante per colture da vaso o simili.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties